Skip to main content

Global Axial Spondyloarthritis Market is Expected to Grow at Significant CAGR 13.44 During the Forecast Period, 2022-2032

 The ankylosing spondylitis and other members of the spondyloarthritis (SpA) family were considered variations of rheumatoid arthritis (RA) up until the early 1960s. As a result, SpA and RA were initially considered to be separate illnesses, but soon after they were found to be inter-connected due to clinical, laboratory, and imaging features. For the last two decades, axial spondyloarthritis (axSpA) has been the subject of major advances in understanding the disease. Additionally, over the years, the distinction between axial and peripheral SpA as well as the connections between non-radiographic and radiographic axSpA has been formalized. In 2009, the term "axial spondyloarthritis" was introduced to describe a diverse disease family that shares clinical and genetic features, such as involvement of the axial skeleton. The following figure shows the evolution of axSpA over the years. The landscape of axial spondyloarthritis is massively growing, with many emerging and legacy companies venturing into the industry with their respective therapeutic portfolio exclusively developed and designed for the treatment of axial spondyloarthritis (axSpA) such as ankylosing spondylitis and non-radiographic axial spondyloarthritis. Additionally, axSpA is associated with several co-morbidities and extra-articular manifestations such as cardiovascular risk, inflammatory bowel disease, and uveitis. Through imaging, genetic, and biomarker studies, researchers are gaining deeper understanding of the biology of axSpA, which will likely resolve many current problems in axSpA diagnosis and classification. Though there is no cure for axSpA, but there are emerging therapies in the global axial spondylopathies market that improves the symptoms, signs, and quality of life in patients with axSpA.

The current study aims to assess the global axial spondyloarthritis market by focusing on the marketed and potential pipeline therapies catering to ankylosing spondylitis and non-radiographic axial spondyloarthritis. The current market for axial spondyloarthritis is majorly dominated by the pharmaceutical companies such as AbbVie Inc., Amgen Inc., Pfizer Inc., Johnson & Johnson Services, Inc., and Novartis International AG.

The global axial spondyloarthritis market is expected to witness high growth, attributing to the growing prevalence of axial spondyloarthritis, favorable regulatory environment, and increase in adoption of biological agents in the field of axial spondyloarthritis. The continued significant investments by the emerging and legacy companies to meet industry demand and the growing adoption of novel therapeutics by the rheumatologists are the major factors propelling the growth of the global axial spondyloarthritis market.

The preceding figure represents the global axial spondyloarthritis market from 2021 to 2032. The market size in 2021 was $1,873.8 million and is expected to reach $7,954.9 million in 2032, growing at a CAGR of 13.44% during the forecast period, 2022-2032.

Comments

Post a Comment

Popular posts from this blog

Personal Care Ingredients Market Size, Share & Trends Analysis Report 2019-2029

The introduction and proliferation of bio-based ingredients in several industries, such as food and beverage, pharmaceuticals, and cosmetics, has been transforming the manufacturing landscape since 2000. Growing consumer inclination toward the adoption of bio-based products due to rising health and environmental concerns is driving the demand for bio-based ingredients in the cosmetics and personal care products. Besides, awareness among consumers regarding the harmful effects of synthetic ingredients chemicals has grown rapidly over the past years. In addition, the availability of green raw materials has also urged large cosmetic firms to develop bio-based cosmetic products. However, limited availability of raw material, due to erratic weather conditions and stringent environmental regulations, can pose substantial hurdles in the production of bio-based ingredients. Thus, leading companies have been focusing on developing new and sustainable ways of producing the ingredi...
Post a Comment
Read more

ADAS and Autonomous Driving Component Market

As per the recent BIS Research report, the ADAS and autonomous driving component market is segmented into component type, level of autonomy, vehicle type, and region for the purpose of study. These segments are further sub-segmented into various categories. In case of market by component type, it is sub-segmented into camera, radar, ultrasonic sensors, LiDAR, and ECU. The use of LiDAR is increasing rapidly in the market owing to reducing cost of LiDAR sensors and their greater range.
Post a Comment
Read more

Driving and Inhibiting Factors of Single Cell Sequencing Market

  A paradigm shift in the dynamics of the market is expected to be witnessed around 2029 with the introduction of imaging solutions and single cell automated system in full scale. The leading players in the market are undertaking the necessary steps to tackle the shift in dynamics and sustain the competition. The global single cell sequencing market is divided into two main categories, instruments and consumables. Kits and consumables market share was valued at $727.2 million of the global single cell sequencing market value in 2018. Also, the kits and consumables is expected to witness impressive growth. The sub-segment is expected to grow with a CAGR of 15.67% during the forecast period 2019-2029. This reflects the dependency of single cell sequencing market on consumables, which is expected to continue to grow in the future. Single cell sequencing workflow is majorly divided into three segments: single cell isolation, single cell preparation, and single cell analysis. Prese...
Post a Comment
Read more